Metformin - A Panacea Pharmaceutical Agent through convergence revolution initiative
Abstract
Keywords
Subject Discipline
References
Watanabe CK. Studies in the metabolic changes induced by administration of guanidine bases. J Biol Chem. 1918; 33:253–65.
Werner EA, Bell J. The preparation of guanidine by the interaction of Dicyanodiamide and ammonium thiocyanate. J Chem Soc Trans. 1920; 117:1133. https:// doi.org/10.1039/CT9201701133
Werner EA, Bell J. The Preparation of Methylguanidine, and of ββ-Dimethylguanidine by the Interaction of Dicyanodiamide and Methylammonium and Dimethylammonium Chlorides Respectively. J Chem Soc Trans. 1922; 121:1790. https://doi.org/10.1039/ CT9222101790
Sterne J. Du nouveau dans les antidiabetiques. La NN Dimethylamine Guanyl guanide (NNDG). Maroc Med. 1957; 36:1295–6.
Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/nda/98/020357s010.cfm
DeFronzo RA, Goodman AM. The multicenter metformin study group efficacy of metformin in patients with noninsulindependent diabetes mellitus New England. Journal Medicine. 1995; 333:541–9. https://doi.org/10.1056/ NEJM199508313330902 PMid:7623902
Lennard MS, Casey C, Tucker GT, Woods HF. Determination of metformin in biological samples. Br J clin Pharmac. 1978; 6:183–5. https://doi.org/10.1111/j.1365-2125.1978. tb00852.x
Gabr RQ, Padwal RS, Brocks DR. Determination of metformin in human plasma and urine by highperformance liquid chromatography using small sample volume and conventional octadecyl silane column. J Pharm Pharmaceut Sci. 2010; 13(4):486–494. https://doi.org/10.18433/J32C71
Frid A, Sterner GN, Londahl M, Wiklander C, Cato A, Vinge E, Andersson A. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function. Diabetes Care. 2010; 33(6):1291–2.https://doi.org/10.2337/dc09-1284 PMid:20215446 PMCid:PMC2875440
Kim HK, Park YS. Plasma concentration of metformin and dexamethasone after administration through osseogate. Drug Delivery. 2017; 24(1):437–42. https://doi.org/10.10 80/10717544.2016.1261380 PMid:28165808
Santoro AB, Stage TB, Struchiner CJ, Christensen MM, Brosen K, Suarez-Kurtz G. Limited sampling strategy for determining metformin area under the plasma concentration-time curve. Br J Clin Pharmacol. 2016 82(4):1002–10. https://doi.org/10.1111/bcp.13049 PMid:27324407 PMCid:PMC5137825
Kumar PP, Murthy TE, Rao MVB. Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study. J Adv Pharm Technol Res. 2015; 6(3):118–24. https://doi.org/10.4103/2231-4040.157982 PMid:26317076 PMCid:PMC4542398
Aburuz S, Millership J, Mcelnay J, Chromatogr B. Determination of metformin in plasma using a new ion pair solid phase extraction technique and ion pair liquid chromatography. Biomed Life Sci. 2003; 798:203–9.https://doi.org/10.1016/j.jchromb.2003.09.043
Cheng C, Chou C. Determination of metformin in human plasma by high-performance liquidchromatography with spectrophotometric detection. J Chromatogr B Biomed Sci Appl. 2001; 762(1):51–8. https://doi.org/10.1016/ S0378-4347(01)00342-5
DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and Cancer risk in diabetic patients: A systematic review and metaanalysis. Cancer Prev Res. 2010; 3:1451–61. https://doi.org/10.1158/1940-6207.CAPR-10-0157 PMid:20947488
Levri KM, Slaymaker E, Last A, Yeh J, Ference J, D’Amico F, Wilson SA. Metformin as treatment for overweight and obese adults: A systematic review. Annals of Family Medicine. 2005; 3(5):457–61. https://doi.org/10.1370/ afm.343 PMid:16189063 PMCid:PMC1466911
van der Aa MP, Hoving V, van de Garde EMW, Boer A, Knibbe CAJ, van der Vorst MMJ. The effect of eighteenmonth metformin treatment in obese adolescents:comparison of results obtained in daily practice with results from a clinical trial. Journal of Obesity. 2016. Article ID 7852648. https://doi.org/10.1155/2016/7852648 PMid:28101379 PMCid:PMC5214571
Pastor-Villaescusa B, Caballero-Villarraso J, Ca-ete MD, Hoyos R, et al. Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: study protocol for a randomized controlled trial Trials. 2016; 17:323. https:// doi.org/10.1186/s13063-016-1403-4 PMid:27432166 PMCid:PMC4950074
Penzias A, Bendikson K, Butts S, et al. Role of metformin for ovulation induction in infertile patients with Polycystic Ovary Syndrome (PCOS): A guideline. Fertil Steril. 2017; S0015-0282(17):30485–5.
Pedersen AJT, Stage TB Glintborg D, Andersen M, Christensen MMH. The pharmacogenetics of metformin in women with PCOS: A randomized trial. Basic Clin Pharmacol Toxicol. 2017. https://doi.org/10.1111/bcpt.12874
O’Brien MJ, Perez A, Scanlan AB, Alos VA, et al. PREVENTDM comparative effectiveness trial of lifestyle intervention and metformin. Am J Prev Med. 2017; 52(6):788–97. https:// doi.org/10.1016/j.amepre.2017.01.008 PMid:28237635
O’Brien MJ, Whitaker RC, Yu D, Ackermann RT. The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Prev Med. 2015; 77:125–30. https:// doi.org/10.1016/j.ypmed.2015.05.017 PMid:26024851 PMCid:PMC4490008
Florez H, Pan Q, Ackermann RT, Marrero DG, et al. Diabetes prevention program research group. Impact of lifestyle intervention and metformin on health-related quality of life: The diabetes prevention program randomized trial. J Gen Intern Med. 2012; 27(12):1594–601. https:// doi.org/10.1007/s11606-012-2122-5 PMid:22692637 PMCid:PMC3509296
The diabetes prevention program research group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005; 28(4):888–94.https://doi.org/10.2337/diacare.28.4.888 PMid:15793191 PMCid:PMC1307521
Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP Kinase- Dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269–73. https://doi.org/10.1158/0008-5472.CAN-06-1500 PMid:17062558
Dowling R, Zakikhani M, Fantus G, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin– dependent translation initiation in breast cancer cells.Available from: http://www.mcgill.ca/pollak-lab/files/ pollak-lab/metformin_inhibits_mammalian_target_of_ rapamycin-dependent_translation_initiation_in_breast_ cancer_cells.pdf
Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology. 2009; 27(20):3297–302. https://doi.org/10.1200/JCO.2009.19.6410 PMid:19487376 PMCid:PMC2736070
Goodwin PJ, Stambolic V, Lemieux J, Chen BE, et al. Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment. 2011; (126):215–20. https://doi.org/10.1007/ s10549-010-1224-1 PMid:20976543
NCT01101438 A Phase III randomized trial of metformin vs placebo in early stage breast cancer: 2010-2017. Available from: https://clinicaltrials.gov/ct2/show/NCT01101438
Lohmann AE, Liebman MF, Brien W, Parulekar WR, et al. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancerpatients in CCTG MA.32. Breast Cancer Res Treat. 2017; 164(2):371–8. https://doi.org/10.1007/s10549-017-4265-x PMid:28447237
Campagnoli C, Pasanisi P, Abba C, Ambroggio S, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer. 2012; 12(3):175–82. https://doi.org/10.1016/j.clbc.2012.03.004 PMid:22607767
Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004; 101:3329–35. https://doi.org/10.1073/pnas.0308061100 PMid:14985505 PMCid:PMC373461
Katiyar S, Liu E, Knutzen CA, Lang ES, Christian R Lombardo CR, et al. REDD1, an inhibitor of mTOR signalling REDD1, is regulated by the CUL4A–DDB1 ubiquitin ligase. EMBO Reports. 2009; 10(8):866–72.https://doi.org/10.1038/embor.2009.93 PMid:19557001 PMCid:PMC2726664
Aryappalli P, Al-Qubaisi SS, Attoub S, George JA, Arafat K, Ramadi KB, Mohamed YA, Al-Dhaheri MM, Al-Sbiei A, Fernandez-Cabezudo MJ, Al-Ramadi BK. The IL-6/ STAT3 signaling pathway is an early target of manuka honey-induced suppression of human breast cancer cells. Frontiers in Oncology. 2017; 14(7):167. https:// doi.org/10.3389/fonc.2017.00167 PMid:28856117 PMCid:PMC5557744
Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, TorresGarcia VZ, Del Barco S, Martin-Castillo B, Menendez JA. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle. 2011 Apr 1; 10(7):1144–51.https://doi.org/10.4161/cc.10.7.15210 PMid:21368581
Algire C, Amrein L, Bazile M, et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene.2011; 30:1174–82. https://doi.org/10.1038/onc.2010.483 PMid:21102522
Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007; 13:433-42. https:// doi.org/10.1016/j.molmed.2007.08.001 PMid:17905659
LeRoith D, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med. 1995; 122:54–9. https:// doi.org/10.7326/0003-4819-122-1-199501010-00009 PMid:7619109
Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA, Bissell MJ. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A. 2006; 103(11):4134–9.https://doi.org/10.1073/pnas.0511342103 PMid:16537497 PMCid:PMC1390746
Widen ElM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulinresistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes. 1992 Mar; 41:354–8. https://doi.org/10.2337/diab.41.3.354 PMid:1551495
Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab. 1986 Dec; 12(6):346–50.PMid:3817257
Drzewoski J, Drozdowska A, Sliwińska A. Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn. 2011; 121:81–7. PMid:21430609
Shariatinia Z, Zahraee Z. Controlled release of metformin from chitosan-based nanocomposite films containing mesoporous MCM-41 nanoparticles as novel drug delivery systems. J Colloid Interface Sci. 2017; 501:60–76.https://doi.org/10.1016/j.jcis.2017.04.036 PMid:28433886
Xiong Y, Zhao Y, Miao L, Lin M, Huang L. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release. 2016; 244(Pt A):63–73.
Snima KS, Jayakumar R, Unnikrishnan AG, Nair SV, Lakshmanan VK. O-Carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells. Carbohydrate Polymers. 2012; 89:1003–7. https:// doi.org/10.1016/j.carbpol.2012.04.050 PMid:24750892
Kumar CS, Raja MD, Sundar DS, Antoniraj MG, Ruckmani K. Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydrate Polymers. 2015; 128:63–74. https://doi.org/10.1016/j.carbpol.2015.04.010 PMid:26005140
Hu J, Prabhakaran M, Tian L, Ding X, Ramakrishna S. Drugloaded emulsion electrospun nanofibers: Characterization, drug release and in vitro biocompatibility. RSC Adv. 2015; 5:100256. https://doi.org/10.1039/C5RA18535A
Nurani M, Akbari V, Taheri A. Preparation and characterization of metformin surface modifiedcellulose nanofiber gel and evaluation of its anti-metastatic potentials. Carbohydrate Polymers. 2017; 165:322– 33. https://doi.org/10.1016/j.carbpol.2017.02.067 PMid:28363556
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 Jun 4; 330(7503):1304– 5. https://doi.org/10.1136/bmj.38415.708634.F7 PMid:15849206 PMCid:PMC558205
Pollak MN. Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discov.2012; 2(9):778–90. https://doi.org/10.1158/2159-8290.CD-12-0263 PMid:22926251
Clinical and biologic effects of metformin in early stage breast cancer 2008-2011. Available from: https:// clinicaltrials.gov/ct2/show/NCT00897884
Effect of metformin on breast cancer metabolism 20102014. Available from: https://clinicaltrials.gov/ct2/show/ NCT01266486
Study of erlotinib and metformin in triple negative breast cancer 2012-2017. Available from: https://clinicaltrials.gov/ct2/show/NCT01650506
Efficacy and safety of adjuvant metformin for operable breast cancer patients 2009-2015. Available from: https:// clinicaltrials.gov/ct2/show/NCT00909506
Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st line treatment of HER2 Neg. Metastatic Breast Cancer Patients (MYME). 20132015. Available from: https://clinicaltrials.gov/ct2/show/ NCT01885013
Metformin and temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma 2008-2013. Available from: https://clinicaltrials.gov/ct2/ show/NCT00659568
A trial of standard chemotherapy with metformin (vs placebo) in women with metastatic breast cancer 20112017. Available from: https://clinicaltrials.gov/ct2/show/ NCT01310231
Metformin pre-surgical pilot study 2009-2017. Available from: https://clinicaltrials.gov/ct2/show/NCT00930579
Khargonekar P, Sinskey A, Miller C, Ranganathan B.Convergence revolution- Piloting the third scientific revolution through start-ups for breast cancer cure. Cancer Sci Res Open Access. 2017; 4(1):1–6. DOI: http://dx.doi.org/10.15226/csroa.2017.00130 https://doi.org/10.15226/ csroa.2017.00130
Ramakrishnan R, Gimbun J, Samsuri F, Narayanamurthy V, Gajendran N, Lakshmi YS, Stranska D, Ranganathan B.Needleless electrospinning technology- an entrepreneurial perspective. Indian J Sci Technol. 2016; 9:1–11. https:// doi.org/10.17485/ijst/2016/v9i15/91538
Ranganathan B, Miller C, Sinskey A. Biocompatible synthetic and semi-synthetic polymers- A patent preliminary analysis. Pharm Nanotechnol. 2017 Oct 23. DOI: 10.2174/2211738505666171023152549. [Epub ahead of print].
Refbacks
- There are currently no refbacks.